Avsnitt
-
An old-rule versus new-rule walk through two documents: the IDSA/SHEA 2021 antibiotic update that made fidaxomicin preferred and demoted metronidazole, and the AGA 2024 guideline that turned fecal microbiota-based therapy into a structured, risk-stratified recommendation whose answer flips entirely on immune status.
-
A stopwatch walk through the time-critical window. The five-minute operational definition, first-line benzodiazepine dosing and route, second-line ASM choices, refractory SE and mandatory continuous EEG, and the ICS 2025 philosophy of hunting for the cause in parallel with stopping the seizure.
-
Saknas det avsnitt?
-
Part two of a two-part stewardship curriculum: syndrome-by-syndrome empiric choices, de-escalation, and usual durations - from CAP and sepsis to endocarditis, bacteremia, and the resistant-organism curveballs, with what actually changed in 2024-2026 (the 2025 CAP steroid reversal, the first-ever IDSA complicated-UTI four-step framework, the seven-day gram-negative bacteremia rule, and the days-old 2026 Staph aureus bacteremia guidance)
-
Part one of a two-part curriculum. How to reason from Gram stain to a narrow, correct regimen: the gram-negative and gram-positive coverage maps, organism-specific first-line logic, the MSSA-off-vancomycin reflex, the resistant-organism villains in plain language, and the four stewardship habits - de-escalation, culture interpretation, IV-to-oral, and source control - with when to call ID
-
The complications deep dive: hepatic encephalopathy and the ammonia trap, reading the ascitic tap and the SBP prophylaxis controversy, variceal bleeding drug and PPI decisions, HRS-AKI with terlipressin guardrails, why chest tubes harm in hepatic hydrothorax, and using ACLF grade rather than MELD alone to drive the transfer and transplant conversation
-
The Surgical Infection Society 2024 update is the antimicrobial and antifungal therapy companion to IDSA 2024 Part 1, which covered diagnosis only; it advises against empiric antifungals in lower-risk community-acquired infection and recommends anidulafungin for higher-risk Candida intra-abdominal infection, all anchored on adequate source control
- Visa fler
